论文部分内容阅读
目的探讨威替米星对妊娠期SD大鼠的胚胎毒性和致畸作用。方法采用大鼠标准致畸试验,79只孕SD大鼠随机分为4组,每组19或20只。威替米星3个剂量组分别给予威替米星30.0、15.0、7.5 mg·kg～,阴性对照组给予生理盐水,于妊娠d 6～15尾静脉注射给药,每日1次。妊娠d 20处死孕鼠,检查母体妊娠与胎鼠畸形情况。结果威替米星各剂量组SD大鼠的孕鼠增重、活胎率、死胎率、吸收胎率和活胎身长与阴性对照组相比无显著差异(P>0.05)。威替米星30.0 mg·kg~(-1)组活胎体重、胎盘重量与阴性对照组比较有显著差异(P<0.05),但无明显的剂量-反应关系。各实验组均未观察到胎鼠明显的外观、脏器以及骨骼的畸形。结论威替米星剂量≤30.0 mg·kg~(-1)无明显的母体毒性和致畸作用,也无明显的胚胎毒性和胎儿毒性。
Objective To investigate the embryotoxicity and teratogenic effects of vetimycin on gestational SD rats. Methods Using standard teratogenicity test in rats, 79 pregnant SD rats were randomly divided into 4 groups with 19 or 20 rats each. The three dose groups of weitilimus were given 30.0,15.0 and 7.5 mg · kg ~ (-1) of vetiverin, respectively. The negative control group was given normal saline and d 6 ~ 15 intravenously once a day for pregnancy. D 20 pregnancy pregnant rats, check maternal pregnancy and fetal malformations. Results The weight gain, live birth rate, stillbirth rate, abdomen birth rate and live birth length of pregnant SD rats in each dose group were not significantly different from those in negative control group (P> 0.05). The body weight and placental weight of 30.0 mg · kg -1 group were significantly different from that of the negative control group (P <0.05), but there was no significant dose-response relationship. The experimental group did not observe the apparent appearance of fetal rats, organs and bone deformities. Conclusion The dose of 30 mg · kg -1 of vetimectin has no obvious maternal toxicity and teratogenicity and no obvious embryotoxicity and fetal toxicity.